Edwards says it expects sales to stall in Q4 as hospital staff shortages stymie TAVR growth

Edwards Lifesciences, one of the top makers of transcatheter aortic valve replacements (TAVR) along with Medtronic, said it expects sales growth to be little changed for the rest of the year after rising 1% in the third quarter as hospital staffing woes cut into procedure volumes.